Revitope is developing conditionally activated, T cell–engaging, bispecific antibodies containing dual tumor-specific antigens and split T cell–targeting paratopes that are unique in their high tolerability. The company is now focused on advancing its therapies to deliver safer and more efficacious therapies especially in solid cancer settings.
